Epoetin beta: Difference between revisions
CSV import |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 23: | Line 23: | ||
[[Category:Recombinant proteins]] | [[Category:Recombinant proteins]] | ||
{{Pharma-stub}} | {{Pharma-stub}} | ||
{{No image}} | |||
Latest revision as of 17:02, 22 March 2025
Epoetin beta is a synthetic, recombinant form of erythropoietin, a hormone naturally produced by the kidneys that stimulates the production of red blood cells. It is used in the treatment of anemia associated with chronic renal failure and in cancer patients receiving chemotherapy.
History[edit]
Epoetin beta was developed in the late 1980s as a result of advances in recombinant DNA technology. It was first approved for medical use in the European Union in 1997.
Medical uses[edit]
Epoetin beta is used to treat anemia in patients with chronic kidney disease, both those who are on dialysis and those who are not. It is also used to treat anemia in cancer patients receiving chemotherapy, and in patients undergoing major surgery to reduce the need for blood transfusions.
Mechanism of action[edit]
Epoetin beta works by stimulating the bone marrow to produce more red blood cells, thereby increasing the oxygen-carrying capacity of the blood. It binds to the erythropoietin receptor on the surface of red blood cell precursors in the bone marrow, triggering their maturation into functional red blood cells.
Side effects[edit]
Common side effects of epoetin beta include headache, hypertension, and flu-like symptoms. Serious side effects can include blood clots, heart attack, stroke, and increased tumor growth in cancer patients.
